AG亚洲游

AG亚洲游·(集团)官方网站/平台/体育/电游/视讯/APP下载

Cell专栏 | 聚焦女性康健领域：子宫内膜异位症的治疗远景【期刊号：2021年第184卷第11期】

2021年6月9日

AG亚洲游·(集团)官方网站/平台/体育/电游/视讯/APP下载

「宇道生物」完成2000万美元A轮融资，建设国际领先变构药物智能化研发平台和管线 | AG亚洲游生意

2021年6月15日

「迪凯尔医疗」完成近亿元C轮融资，提供数字化口腔莳植手术全流程解决计划 | AG亚洲游生意

“谢谢AG亚洲游资源为本轮融资做出的起劲，从项目启动到交割历程中AG亚洲游的专业能力让团队很是认可。希望AG亚洲游越做越好，成为细分行业领先的投融资照料。”——迪凯尔医疗总司理陈云

克日，苏州迪凯尔医疗科技有限公司（下称“迪凯尔”）宣布完成近亿元人民币的C轮融资。本轮融资由恒旭资源事投，现有股东汇鼎资源跟投，AG亚洲游资源担当独家财务照料。本轮融资所筹资金将用于扩大团队规模，推进市场渠道建设、拓展产品管线等。
迪凯尔建设于2010年，是一家专注于手术导航机械人研发和工业化的高科技医疗器械公司。公司现阶段已打造围绕口腔莳植手术的多款焦点产品，未来将基于导航机械人看法进一步拓展至其他科室应用场景。
我国口腔行业供应端现在还保存诸多缺乏，对诊疗流程标准化以及手术清静性、有用性等效果均有影响。公立医院及私立诊所亟需提高营运效率，数字化和智能化成为生长偏向，催生盘算机辅助导航手艺的普及，在莳植牙赛道尤为显着。动态可视导航系统在微创、清静性上大大提升病人体验，并大大提升基础医生效率，且实现莳植牙手术顺应症全笼罩，知足患者多元化诊疗需求。现在，迪凯尔已经建设起平均从业履历15年以上的专业口腔团队，从口腔莳植手术系统研提倡步，并扩展至于其他科室。公司焦点产品“易植美”作为海内唯一获批三类注册证的口腔莳植手术实时导航系统，已进入北大、武大、华西等顶级口腔医院，多年来实现销量稳固高增添。
阻止现在，迪凯尔已累计申请发明专利40余项，公司一方面通过手术教学系统和正畸营业进一步牢靠口腔领域龙头职位；另一方面也起劲推进手术导航系统在其他科室的应用，力争实现多科室周全结构，形成协同效应。

迪凯尔总司理兼董事长陈云体现：“我们很是谢谢恒旭资源和汇鼎资源关于本轮融资的鼎力大举支持。迪凯尔为莳植患者提供便捷、清静的手术选择。我们已上市的口腔莳植手术导航系统及口腔手艺训练及实时评估系统均抵达国际领先水平，为患者提供更高的手术精准度与定制化效劳。未来，迪凯尔将在现有牙科产品一直迭代的基础上，充分验展手术机械人平台的通用性，致力于成为一家综合性平台型公司。
恒旭资源董事长陆永涛体现：“我国莳植牙市场正处在高速生耐久，在老龄化攻击下，莳植需求将进一步加速释放。现在，后疫情时代的牙科下半场竞争已经集中在数字化领域，我国市场对数字装备的需求大幅增添。迪凯尔作为最早结构牙科数字化领域的企业之一，现在已乐成在产品研发和市场推广两头建设高壁垒，形成焦点竞争力。迪凯尔发力攻关的手术机械人是恒旭在数字化医疗领域关注的重点赛道，我们期待团队的一连立异能力，信托迪凯尔能成为一家有国际化影响力的机械人公司。
汇鼎资笔莆理合资人何欣博士体现：“手术数字化是生长趋势，手术导航系统提高了医生的诊疗准确度，降低医生学习曲线；同时让手术更微创，术中反响更实时，利好患者快速实现术后康复。迪凯尔的产品履历了研发期、市场导入期，已与牙科莳植全流程细密嵌合；让临床医生愿意用、用得好。这是汇鼎资源第二次与迪凯尔团队相助，我们看好迪凯尔团队一连商业化能力，也对公司基于底层导航手艺的产品拓展充满信心，期待越来越多的牙科患者能从公司产品中获益。”

关于恒旭资源

恒旭资源（中基协备案号：P1070270）是上海汽车集团股份有限公司（600104.SH）旗下的私募股权投资平台，依托上汽集团整体优势，公司以投资人收益最大化为目的，结构先进制造、医疗康健、前沿科技、大消耗等战略新兴工业，为上汽集团立异工业链的生长和出行生态圈的完善做出孝顺。恒旭资源在医疗行业的结构包括爱博医疗、安智因生物、长风药业、德美医疗、高诚生物、魅丽纬叶、瑞博生物、亚虹医药、微知卓生物等多家优异企业。

关于汇鼎资源

汇鼎投资汇聚中国TOP投资机构高级合资人团队，由拥有多年创业运营履历，外洋手艺中国落地履历及行业资源的团队倾力打造�；愣χ铝τ谡先蛞搅剖忠樟⒁�，聚焦中国医疗工业升级，以汇聚资源，鼎力大举相助，帮助中国企业成为行业龙头为使命。

[:en]We have been working intensively with DAS Capital to identify, select and approach potential financial/strategic investors for our breakthrough technology. We are deeply impressed by the team’s professionalism, and we believe DAS Capital will become a national-leading Financial advisor in the industry.

——Yun Chen, Managing Director at DCARER

@DAS Capital’s client, @DCARER recently finished its RMB 100 million Series C funding round. The investors are composed of @SAIC Hengxu Capital, a fund of funds under SAIC Motor Corporation Limited (SHA: 600104), and current shareholder, Hyfinity Investments. The funds raised will be used to develop current product pipelines, explore new customers, and expand the research and sales team.

Founded in 2010, DCARER is a high-tech medical device company focusing on the R&D and industrialization of surgical navigation robots. At this stage, DCARER’s core products are mainly used during oral implant surgery. The company will further extend its product pipelines to application scenarios in other departments including cosmetology, orthopedics, etc.

China’s oral industry still faces a lot of shortcomings on the supply side, which affects the standardization of the diagnosis/treatment process and surgery’s safety and effectiveness. The demand for improving surgery efficiency from public and private hospitals generates large unmet needs of digitalization. As a result, the computer-aided navigation technology will be widely used to support the operation, especially in the dental implant segment. While the patients benefit from minimal invasiveness and safe surgeries, dentists improve their efficiency and could achieve full coverage of indications to tailor services with the help from the latest technology, the dynamic visual navigation system.

DCARER has established a professional execution team with an average experience of more than 15 years. The company’s competitive product?YiZhiMei (“易植美”), currently the only NMPA approved domestic real-time navigation system (level 3) for dental implant surgery, has already established reputation in the high-end market. DECARER has long-term cooperative relationships with top dental hospitals, such as PKU Hospital of Stomatology(“北京大学口腔医院”), and West China Hospital of Stomatology Sichuan University(“四川大学华西口腔医院”). YiZhiMei has achieved high growth in sales for many years since its launch.

Up to now, DCARER has applied for more than 40 invention patents. Strategically the company will further consolidate its leading position in the oral industry through its surgical teaching system and orthodontic robots; on the other hand, it aims to build a comprehensive product layout in multiple departments to benefit from cost synergies.
Yun Chen, Chairman of DCARER, said: ‘We appreciate Hengxu Capital and Hyfinity Investments for their strong support in this round of financing. DCARER is dedicated to providing convenient and minimally invasive surgery options for Chinese patients. Our dental surgical navigation system has reached the leading level worldwide with highly accurate customized services. In the future, we will continuously upgrade our dental robots, and we are committed to becoming a comprehensive surgical platform.’

Yongtao Lu, Chairman at SAIC Hengxu Capital, said: ‘China’s dental implant market has developed rapidly in recent years, with the demand being further accelerated under the impact of growing aging population. Right now, the competition is concentrated on digital healthcare. As an industry pioneer, DCARER has established its wide moat and makes it hard for competitors to catch up. We think that robots will be the key driver for future market development and we strongly believe that DCARER will become a global leading company in this industry.’

Dr. Xin He, Managing Partner of Hyfinity Investments, said: ‘The surgical navigation system improves surgery accuracy and reduces doctor’s learning curve. At the same time, it makes the operation more minimally invasive, the intraoperative feedback more real-time and the postoperative rehabilitation process more quickly. DCARER products are suitable during dental implant surgery, thus increases dentist’s willingness and proficiency. This is the second time that we choose to co-operate with DCARER. We are optimistic about the company’s continuous commercialization capabilities. We look forward to witnessing more and more dental patients benefiting from the company’s products.’

【网站地图】【sitemap】